DIRS.INFO The most relevant business & tech news

☆ Close Friends, Competing for Coveted Olympic Spots. Who Would Make It?
▼ + stars: | 2024-05-08 | by ( Talya Minsberg | ) www.nytimes.com time to read: +1 min

Conner Mantz’s arms were shaking as he warmed up for the Olympic marathon trials in Orlando in February. Mr. Mantz, 27, of Provo, Utah, looked over to his close friend, Clayton Young, who was stretching next to him. They had raced for the same prize money, fought for the same spots on the podium — and formed a bond so strong that other runners said they wished they could replicate it. Now, they hoped to get each other to the marathon at the Olympic Games in Paris. They had a real shot: Mr. Mantz was a favorite to qualify, and Mr. Young was a strong contender.

Persons: Conner Mantz’s, Mantz, Clayton Young, Young Organizations: Mr, Olympic Games Locations: Orlando, Provo , Utah, Paris

☆ The top 9 cities tech talent is moving to — and 9 places they're leaving
▼ + stars: | 2024-04-30 | by ( Kelsey Vlamis | ) www.businessinsider.com time to read: +3 min

New York, Austin, and LA were the top cities tech talent moved to in 2023, according to a report. Several places attracting tech workers are "blue island" cities in red states. 1 place tech workers moved to in 2023 was New York City, according to a recent SignalFire report. AdvertisementThe top nine cities tech workers relocated to were:New York City, New YorkAustin, TexasLos Angeles, CaliforniaDenver, ColoradoSan Diego, CaliforniaMiami/Fort Lauderdale, FloridaDallas/Fort Worth, TexasNashville, TennesseeTampa/St. AdvertisementSeveral of the cities attracting tech workers also happen to be "blue island" cities located in red states, such as Austin, Nashville, Tampa, and Miami.

Persons: —, Austin Organizations: Boston, Service, Tech, San, Business, St . Petersburg , Florida New, Los, California Portland , Oregon Detroit , Michigan Provo , Utah San, Seattle, York Locations: York, Austin, LA, San Francisco, Seattle, Miami, New York City, San Francisco Bay, California, New York , Texas , California, Florida, New York City , New York Austin , Texas Los Angeles , California Denver , Colorado San Diego , California Miami, Fort Lauderdale , Florida Dallas, Fort Worth , Texas Nashville , Tennessee Tampa, St . Petersburg , Florida, St . Petersburg , Florida New York, Los Angeles, Francisco , California Seattle, Washington Boston , Massachusetts Phoenix , Arizona Washington, DC Sacramento, California Portland , Oregon Detroit , Michigan Provo , Utah, California Portland , Oregon Detroit , Michigan Provo , Utah San Francisco, New York, Boston, San Francisco and California, Texas, York City, Nashville, Tampa, Utah , Idaho, Arkansas

People are surprised to learn that Mari Murdock, 36, is a professional game master, a role in which she organizes and narrates tabletop roleplaying games like Dungeons & Dragons. Dungeons & Dragons is an open-ended tabletop game in which the narrative is shaped by the players' choices, whether that's through combat, puzzles or negotiation. But as Murdock played tabletop games through the 2010s, she grew more confident in the skills it takes to run a good game. The timing was fortuitous, as tabletop gaming became more popular during the pandemic. For Murdock, gaming allows you to immerse yourself in "a pretend situation where you are imagining that you are someone else.

Persons: Mari Murdock, Graham Merwin, Murdock, — it's, Scott, Murdock's, Mari, she'd, Dax Levine, —, Levine, Max, we've, it's Organizations: CNBC, Westminster University, Brigham Young University, Hawaii, BYU, Dragons, Guinness World Records, &, PayPal, Hulu, Spotify, Amazon Prime, Max Insurance, Relief Society Locations: Utah, Salt Lake City, Michigan, Hawaii, Japan, Scott, Provo , Utah

☆ Eli Lilly's top-selling drug last year is softening. But it may not matter for the stock
▼ + stars: | 2024-04-12 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. JPMorgan flagged similar trends for Trulicity, which led all Lilly drugs with $7.13 billion in sales for all of 2023. The thesis is predicated on Eli Lilly growing faster than the broader pharmaceutical industry for years to come. Over the past three years, shares of Eli Lilly have soared nearly 300%, compared with a 24% gain for the S & P 500 . A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

Persons: Eli Lilly, Wells, Lilly, Mounjaro, Jim Cramer, tirzepatide, Zepbound, Eli Lilly's, Novo, Wegovy, drugmaker, Jim Cramer's, Jim, Eli Lilly Pharmaceutical, George Frey Organizations: Wall Street, JPMorgan, Club, Novo Nordisk, Novo, BMO Capital Markets, Drug Administration, FDA, The Club, CNBC Locations: Wells Fargo, Trulicity, Tirzepatide, Danish, Lilly, Provo , Utah

☆ Palo Alto, Eli Lilly and Eaton are up big. Here are entry prices for new investors
▼ + stars: | 2024-02-11 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

Palo Alto Networks , Eli Lilly , and Eaton rallied hard over the past 12 months — up 127%, 117% and 66%, respectively. This $315 level is also close to the 50-day simple moving average (red line). Eli Lilly Two potential entry points: $617 (the 50-day simple moving average) and $541 (the 200-day simple moving average) The 50-day simple moving average is $617, a roughly 16.5% pullback from current levels, while the 200-day simple moving average is $541, a 27% decline. Instead, keep a close eye on that 50-day moving average, looking for that gap between the moving average and the stock price to narrow. As we can see, $242 represents the current 50-day moving average, with $240 representing a level of resistance shares recently surpassed.

Persons: Eli Lilly, Eaton, it's, pullbacks, PANW, Mounjaro, they've, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: Palo Alto Networks, Big Tech, Palo Alto, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: Provo , Utah

☆ 11 US cities with the best mix of jobs, pay, and affordability
▼ + stars: | 2024-02-07 | by ( Noah Sheidlower | ) www.businessinsider.com time to read: +7 min

Raleigh and Boise also placed high for large cities, while Idaho Falls ranked first for small cities. Per the rankings, only 11 large cities and seven small cities were classified as Tier 1, placing high among many metrics. Big cities also saw their tech sectors grow much faster than small cities. Philadelphia jumped 130 places between 2023 and 2024 in the large cities list, while Manhattan, Kansas, rose 160 places for small cities. AdvertisementFour of the top seven small cities were in Idaho, exemplified by Coeur d'Alene, Twin Falls, and Pocatello.

Persons: Austin, —, Milken, hasn't, Richmond , Virginia —, Paso Robles, El Centro Organizations: Milken Institute, Raleigh, Idaho Falls, Service, Boise, Bureau of Labor Statistics, Idaho National Laboratory, Obispo Locations: Boise, Austin, Raleigh, Los Angeles, Long, Glendale and New York, Jersey, White, Sunbelt, Provo, Orem, Utah, Salt Lake City, Elgin , Illinois, Houston, , Texas, Richmond , Virginia, Charleston, North Charleston, South Carolina, Philadelphia, Manhattan , Kansas, Wichita, Lawrence, Kansas, Idaho, Coeur d'Alene, Twin Falls, Pocatello . Idaho, California, San Luis, Arroyo Grande, Modesto, El

☆ We're raising our price target on Eli Lilly by $120 after its excellent quarter
▼ + stars: | 2024-02-06 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +10 min

Bottom line Eli Lilly delivered a strong report Tuesday. Still, it's not a surprise to see shares of Eli Lilly fall nearly 2% Tuesday, to around $694 each. Despite doubling manufacturing capacity year over year in 2023, Eli Lilly said demand for its GLP-1s is "likely to outpace supply" this year. We're raising our Eli Lilly price target to $750 a share from $630, while reiterating our 2 rating on the stock, meaning we'd wait for a pullback before adding to our position. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly's, Lilly's, Eli Lilly, Mounjaro, Zepbound, it's, —, Jim Cramer, Anat Ashkenazi, NASH, Lilly, Jim, Jardiance, Verzenio, Trulicity, donanemab, Ashkenazi, Jim Cramer's, George Frey Organizations: Revenue, LSEG, U.S, Novo Nordisk, Food and Drug Administration, Analysts, Investors, FDA, CNBC, Bloomberg, Getty Locations: Mounjaro's, U.S, Mounjaro, Trulicity, Provo , Utah

☆ 8 more of our stocks report earnings next week. Here's what we want to see
▼ + stars: | 2024-02-03 | by ( Zev Fima | ) www.cnbc.com time to read: +13 min

The three major averages posted gains for the fourth week in row, lifted by strong quarterly earnings results for most of the Big Tech companies and a strong jobs report. A weaker ADP Employment report on Wednesday provided no read-through to the monster January jobs report Friday. Here's what we're keeping an eye on in the coming week: 1. Earnings: It's another big earnings week head for the portfolio, with 8 more of our companies reporting. Consistency is what we appreciate most from nat gas giant Linde , so we're hoping for another quarter of solid earnings growth Tuesday.

Persons: Estee Lauder, Eli Lilly, Mounjaro, Nelson Peltz, Estée Lauder, Tyson, CARR, Jacobs, Willis Towers Watson, Edwards, Walt Disney, Oscar Health, Philip Morris, Armour, BAX, BILL, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: Big Tech, Dow Jones Industrial, Nasdaq, PMI, Apple, Starbucks, Procter, Gamble, GE Healthcare, DuPont, Linde, Ford, General Motors, Trian Partners, Disney, ESPN, Wynn Resorts, Wynn, Vegas, Prix, Estée Lauder Companies, Caterpillar, McDonalds Corp, Allegiant Travel, Bowlero Corp, Tyson Foods, TSN, Air Products & Chemicals, IDEXX Laboratories, CNA Financial Corp, CNA, Timken Company, Graham Corporation, Mesa Laboratories, Sphere Entertainment, Loews Corp, Technologies, Vertex Pharmaceuticals, Semiconductors, Simon Property Group, Amkor Technology, FMC Corporation, FMC, BellRing Brands, Crown Holdings, ChampionX Corporation, Golub Capital BDC, Flexsteel Industries, Kilroy Realty Corp, Gladstone Capital Corp, Unibanco, S.A, Snack Foods Corp, Kimball Electronics, Skyline Corp, Cabot Corporation, Simpson Manufacturing Co, Varonis Systems, Co, GE HealthCare, Linde plc, LIN, Spotify Technology S.A, BP, Hertz Global Holdings, AeroSystems Holdings, Toyota Motor Corp, Cummins, CMI, Software Technologies, AGCO Corporation, Carrier Global Corporation, Lear Corp, CONSOL Energy, Centene Corporation, Gartner, Arcbest Corp, CTS Corporation, Energizer Holdings, Hamilton Lane Incorporated, KKR, Precision Drilling Corporation, Frontier Group Holdings, Waters Corp, Alfa Laval, Aramark Holdings Corp, FirstService Corporation, Garden Sports Corp, New Jersey Resources Corp, nVent Electric plc, PJT Partners, Resources, Sensata Technologies, Ford Motor Company, Enphase Energy, Grill, VF Corp, Edwards Lifesciences Corp, Gilead Sciences, Lumen Technologies, Cognizant Technology Solutions Corp, Weatherford International plc, Amcor plc, Arrowhead Pharmaceuticals, Advanced Energy Industries, Uber Technologies, CVS Health, Roblox Corporation, Ares Capital Corp, Bunge, XPO Logistics, Scotts Miracle, Gro Company, Berry Global, Flex LNG, Equinor ASA, Griffon Corporation, OneMain Holdings, Brookfield Asset Management, Emerson Electric Co, Hilton Worldwide Holdings, Reynolds Consumer Products, Silicon Laboratories, Brands, Sciences, CDW Corp, Fox Corporation, WYNN, PayPal, Arm Holdings plc, ARM, Axcelis Technologies, Mattel, Paycom, Annaly Capital Management, McKesson Corp, Health Corporation, O'Reilly Automotive, Allstate Corp, Fluence Energy, Power Systems, Digital Turbine, Blue Bird Corp, Everest Group, Omega HealthCare, Coty, COTY, ConocoPhillips, Cameco Corp, Philip Morris International, Spirit Airlines, Hershey Company, Lightspeed Commerce, Aurora Cannabis, Lincoln National Corp, P, Tenet Healthcare Corp, Asbury Automotive Group, Arrow Electronics, Baxter International, PetMed, Boyd Gaming Corp, FirstEnergy Corp, Motorola Solutions, Terex Corp, PepsiCo, Growth, AMC Networks, Owl, American Pipeline, TELUS International, Magna International, Newell Brands, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: U.S, China, Macau, Wynn Macau, Valvoline, VVV, ALFVY, Madison, New Jersey, Gilead, Ceridian, ORLY, Paycor, Aurora, Provo , Utah

☆ Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club
▼ + stars: | 2024-01-31 | by ( Sam Meredith | ) www.cnbc.com time to read: +1 min

A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. Norway's giant wealth fund, the world's largest, touted the possibility that Danish drugmaker Novo Nordisk and U.S. rival Eli Lilly could be on course to become the first healthcare members of the trillion-dollar club. Novo Nordisk, Europe's largest firm by market capitalization, on Wednesday reported stronger-than-anticipated 2023 earnings, as sales of its hugely popular drug Wegovy continued to soar. The largest pharmaceutical company in the world by market value, Eli Lilly currently stands at roughly $612 billion. NBIM, the world's biggest single stock market investor, holds a 2.5% stake in Novo Nordisk and a 0.98% stake in Eli Lilly, according to LSEG data.

Persons: Eli Lilly, Wegovy, Gemma Game, Eli Lilly's Zepbound Organizations: Novo Nordisk, Pharmacy, Norges Bank Investment Management, Nordisk's Ozempic Locations: Provo , Utah, U.S, Danish, Europe's

☆ How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug
▼ + stars: | 2024-01-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

They're also at the heart of our investment thesis in Eli Lilly, a longtime Club holding. Shares of Eli Lilly have soared nearly 80% over the past 12 months, including a more-than-5% gain in January alone. In November, Eli Lilly indicated it was on track to meet the goal, which also was made possible by upgrades to existing facilities. Eli Lilly has used KwikPen technology for other diabetes treatments, such as insulin injections, for many years. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly, —, Eli Lilly's, They're, FactSet, Lilly's, Dave Ricks, Ricks, Lilly, there's, Morgan Stanley, Eli, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: CNBC, FDA, Novo Nordisk, JPMorgan Healthcare Conference, Research, Barclays, RTP, —, U.S, JPMorgan, Bloomberg, Getty Locations: Danish, Indianapolis, North Carolina, Carolina, Concord , North Carolina, Germany, U.S, Australia, Canada, KwikPen, Provo , Utah

☆ Small cities to watch in 2024: Why these 4 underrated locales are drawing movers from big cities
▼ + stars: | 2024-01-22 | by ( Jordan Pandy | ) www.businessinsider.com time to read: +5 min

Some movers are giving up on Los Angeles and Dallas for smaller cities in Texas and Nevada. The cherry on top is the relatively affordable real estate compared to other cities. That lump sum of cash got some movers in the door, but the booming job market and relatively affordable housing are keeping them there. New Braunfels, Texas Regan Bender/ShutterstockPeople flock to the Lone Star state, but not always to the usual destinations. New Braunfels, Texas, attracts more movers than Austin and Dallas today with its relatively affordable homes and dearth of job opportunities.

Persons: —, Vegas , Nevada Wendy Lee Las, Richard Katz, Katz, Andrew Arevalo, Adam Outlaw, Outlaw, New Braunfels , Texas Regan Bender, Anna Lagos, we'd, Jean Tanner Organizations: Service, Austin, . Topeka , Kansas Getty, Topeka, Lone Star, Adobe, Meta, Microsoft Locations: Los Angeles, Dallas, Texas, Nevada, New York, Austin, Las Vegas, New Braunfels , Texas, Topeka , Kansas, Provo , Utah, Vegas , Nevada, Sin, Virginia, Vegas, . Topeka , Kansas, Topeka, Boston, California, San Antonio, New Braunfels, Lagos, Denver, Salt Lake City, Provo

At issue is whether U.S. bankruptcy law allows Purdue's restructuring to include legal protections for the members of the Sackler family, who have not filed for personal bankruptcy. Members of the Sackler family have denied wrongdoing but expressed regret that OxyContin "unexpectedly became part of an opioid crisis." They said in May that the bankruptcy settlement would provide "substantial resources for people and communities in need." The administration told the Supreme Court that Purdue's settlement is an abuse of bankruptcy protections meant for debtors in "financial distress," not people like the Sacklers. The administration has also alleged that the Sackler family members withdrew $11 billion from Purdue before agreeing to contribute $6 billion to its opioid settlement.

Persons: painkiller, George Frey, Joe Biden's, Sackler, Biden, OxyContin, John Kruzel, Andrew Chung, Will Dunham Organizations: Purdue Pharma L.D, REUTERS, Rights, Purdue Pharma, WASHINGTON, U.S, Supreme, Purdue, Circuit, Thomson Locations: Provo , Utah, U.S, Stamford , Connecticut, Manhattan

☆ US Supreme Court to scrutinize controversial opioid crisis settlement that would give Sackler family immunity
▼ + stars: | 2023-12-04 | by ( Samantha Delouya | ) edition.cnn.com time to read: +7 min

Barring individual victims from pursuing their own lawsuits against the Sackler family “raises serious constitutional questions,” the department argued. OxyContin’s commercial success helped the Sackler family earn billions of dollars and the family became known for philanthropy around the world. As the country’s opioid crisis worsened, attention shifted to the role played by Purdue Pharma and the Sackler family. Many of the suits allege that the Sackler family knew of OxyContin’s addictive properties but, nevertheless, continued to promote the drug. The Supreme Court hearing comes at a time of devastating losses due to drug overdoses in the US.

Persons: Los Angeles CNN —, Sackler, Mortimer, Raymond Sackler, “, George Frey, Elizabeth Prelogar, ” Anthony Casey, , –, Purdue Frederick, ” Lindsey Simon, ” Organizations: Los Angeles CNN, Purdue, New, US, US Justice Department, Purdue Pharma, Supreme, Knoa Pharma, Purdue Pharma L.P, Bloomberg, Sackler, ”, University of Chicago, school’s, Law, Finance, Guggenheim, Centers for Disease Control, “, Emory University Locations: New York, Purdue, Provo , Utah, U.S, United States, Paris

☆ Feeling read by your Spotify city? You just have the musical taste of a depressed liberal college student.
▼ + stars: | 2023-11-30 | by ( Sebastian Cahill | ) www.businessinsider.com time to read: +3 min

Spotify Wrapped day is one of the most exciting holidays of the year. AdvertisementAh, Spotify Wrapped. Advertisement"Everyone complaining about getting Provo in their spotify wrapped needs to just accept the fact that they have terrible taste in music," said one commentator. "going to college in Davis and waking up seeing everyone bashing it because they got it on their spotify wrapped is so funny," said another X user. Other people theorized that the frequency of college towns being picked was due to the generally lower age range of Spotify users.

Persons: —, San Luis Obispo Organizations: Spotify, Service, Brigham Young University, University of Vermont, University of California, —, Provo, spotify Locations: Berkeley, Mexico City, screenshotting, provo, Burlington , Vermont, burlington, Madison , Wisconsin, Provo , Utah, Burlington ; Berkeley , California, Cambridge , Massachusetts, — Madison , Wisconsin, San Luis, Davis , California, Davis

REUTERS/George Fre/File Photo Acquire Licensing RightsNov 27 (Reuters) - Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's (LLY.N) Mounjaro than those taking Novo Nordisk's (NOVOb.CO) popular rival weight loss drug, according to an analysis of health records and other data. After 3 months of treatment, patients on Mounjaro had lost an average of 2.3% more body weight than those taking Ozempic, the study also found. By 6 months, the difference had widened to 4.3%, and by 12 months, the Mounjaro group had lost an average of 7.2% more weight. An Eli Lilly spokesperson said the company does not promote or encourage the off-label use of any of its medicines, although its drug is now approved for weight loss. A trial is underway comparing the weight loss formulations of the two injected medicines in patients overweight or obese but without type 2 diabetes.

Persons: Lilly, George Fre, Eli Lilly's, Mounjaro, Eli Lilly, Nancy Lapid, Bill Berkrot Organizations: Novo Nordisk, Pharmacy, REUTERS, Novo, Thomson Locations: Provo , Utah, U.S

REUTERS/George Frey/File Photo Acquire Licensing RightsNov 21 (Reuters) - Tema ETFs has launched a new exchange traded fund (ETF) that tracks popular drugmakers like Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N), aiming to tap into growing demand for their weight-loss and diabetes drugs. The Tema Cardiovascular & Metabolic ETF (HRTS.O) invests in companies tackling diabetes, obesity and cardiovascular diseases, according to the New York-headquartered platform's website. The advances of the class of weight-loss and diabetes therapies known as GLP-1 receptor agonists, are only the tip of the iceberg, said David K. Song, investment partner and head of life sciences at Tema ETFs. The Tema fund has a net expense ratio of 0.75%. Reporting by Bansari Mayur Kamdar in Bengaluru; Editing by Emelia Sithole-MatariseOur Standards: The Thomson Reuters Trust Principles.

Persons: Lilly, George Frey, Eli Lilly, Mounjaro, David K, Morgan Stanley, Bansari Mayur, Emelia Sithole Organizations: Novo Nordisk, Pharmacy, REUTERS, Metabolic, Morgan Stanley Research, VanEck Pharmaceutical, Thomson Locations: Provo , Utah, U.S, Tema, Novo, New York, Bengaluru

Analysts attended earnings calls in the third quarter armed with questions for healthcare and consumer companies about the potential effect on their sales from the growing popularity of these drugs, known as GLP-1 agonists. A Reuters analysis of earnings transcripts for the third quarter showed "GLP-1" or alternatives like "obesity" or "weight-loss medications" were mentioned 256 times across 29 U.S. and European healthcare and consumer companies. That's more than double the mentions for the second quarter, when those phrases came up 127 times. While some consumer companies have talked about factors such as fewer calories being consumed, "these kind of large extrapolations" seem to be a bit of a stretch, said BMO Capital analyst Evan Seigerman. For big pharma manufacturers like Pfizer (PFE.N) and Amgen (AMGN.O), analyst questions were aimed at their obesity drug candidates.

Persons: Lilly, George Frey, Jeff Jonas, it's, Eli Lilly's, John Furner, Mondelez, Eli Lilly, Evan Seigerman, LVMH, Rajesh Kumar, Jonas, Bhanvi Satija, Savyata Mishra, Arpan Varghese, David Gaffen, Shounak Organizations: Novo Nordisk, Pharmacy, REUTERS, Gabelli, Novo, Walmart, Walmart U.S, Hershey, Truist Securities, Krispy, BMO Capital, Danish, pharma, Pfizer, Devices, HSBC, Thomson Locations: Provo , Utah, U.S, United States, Novo, Bengaluru

☆ German regulator eyes Ozempic export ban amid shortages across Europe
▼ + stars: | 2023-11-15 | by ( Ludwig Burger | ) www.reuters.com time to read: +5 min

Use of Ozempic for weight loss has caused shortages across Europe. Novo Nordisk, which has earmarked $6 billion to boost production in Denmark, said last week the industry was far from being able to produce enough weight-loss drugs to meet global demand. The German association of drug wholesale distributors PHAGRO said in a statement that there was no certainty that exports were causing the shortages. Portugal, Poland, Romania, Belgium, Slovakia and Spain, in turn, have rules in place that likely make it impossible to export the drug, Affordable Medicines said. It also urged "all relevant actors" not to export the drugs.

Persons: George Frey REFILE, Spiegel, Lilly, Karl Broich, Eli Lilly's, tirzepatide, BfArM's Broich, Broich, PHAGRO, Germany's BfArM, Ludwig Burger, Miranda Murray, Patricia Weiss, Matthias Williams, Sharon Singleton Organizations: Novo Nordisk, Pharmacy, REUTERS, BfArM, EU, Novo Nordisk's, Spiegel, European Union, Medicines, Thomson Locations: Provo , Utah, U.S, FRANKFURT, United States, Europe, Britain, Belgium, Germany, Norway, Denmark, Medicines Europe, Austria, France, Greece, Czech Republic, Portugal, Poland, Romania, Slovakia, Spain, Frankfurt, Berlin

☆ German drug regulator considering export ban on Ozempic
▼ + stars: | 2023-11-15 | by ( ) www.reuters.com time to read: +1 min

[1/2] A box of Ozempic, a semaglutide injection drug used for treating type 2 diabetes and made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey REFILE - CORRECTING MONTH/File Photo Acquire Licensing RightsCompanies Novo Nordisk A/S FollowBERLIN, Nov 15 (Reuters) - The head of Germany's drug regulator BfArM is considering an export ban on Novo Nordisk's (NOVOb.CO) diabetes drug Ozempic, which is in high demand for its weight-loss benefits, to prevent a further worsening of a supply shortage. There is a risk of Ozempic being moved out of the country because it is cheaper there than in many other countries, BfArM president Karl Broich told Spiegel magazine. "We know that some of the syringes that are supplied to Germany for our diabetes patients are channelled to other European countries or the United States," he told Spiegel on Wednesday. We need the medication for the care of diabetes patients and not as a lifestyle drug."

Persons: George Frey REFILE, Karl Broich, Spiegel, Miranda Murray, Ludwig Burger Organizations: Novo Nordisk, Pharmacy, REUTERS, Novo Nordisk's, Spiegel, Ludwig Burger Our, Thomson Locations: Provo , Utah, U.S, Germany, United States

☆ Belgium bans use of Ozempic for weight loss until summer
▼ + stars: | 2023-11-14 | by ( Marine Strauss | ) www.reuters.com time to read: +1 min

Boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. Ozempic is approved to treat Type 2 diabetes but has increasingly been prescribed "off-label" to treat weight loss because it has the same active ingredient as Novo's hugely popular - and scarce - anti-obesity drug Wegovy. In Britain, doctors and prescribers, including private online pharmacies, have been ordered to stop prescribing Ozempic to people who don't have type 2 diabetes as soon as possible. They are also banned from starting new patients with type 2 diabetes on the medicine for as long as the shortage lasts. Last month, Belgium's federal medicine agency recommended doctors and pharmacists only prescribe Ozempic to diabetic patients due to the surge in demand.

Persons: George Frey, Ozempic, Marine Strauss, Mark Potter Organizations: Novo Nordisk, Pharmacy, REUTERS, Marine, Thomson Locations: Provo , Utah, U.S, Belgium, Britain

☆ FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug
▼ + stars: | 2023-11-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

George Frey | ReutersThe Food and Drug Administration on Wednesday approved Eli Lilly 's blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S. The FDA said the approval was based on two of Eli Lilly's late-stage trials on tirzepatide, which evaluated its effects on weight loss after 72 weeks. Higher doses of the drug were associated with even more weight loss, with a 15-milligram dose leading to 22.5% weight loss on average. The bigger issue is that many insurance companies are dropping weight loss drugs from their plans. Preliminary data is already available: A recent late-stage trial found that Novo Nordisk's weight loss drug Wegovy reduced the risk of cardiovascular events such as heart attack and stroke by 20%.

Persons: George Frey, Eli Lilly, John Sharretts, Eli Lilly's, Wegovy, Lilly, Mike Mason, Eli Lilly Diabetes Organizations: Novo Nordisk, Pharmacy, Reuters, Food, Drug Administration, U.S, FDA's Center, Drug, FDA, Obesity Locations: Provo , Utah, U.S, United States

☆ Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly on Thursday said supply of its blockbuster diabetes drug Mounjaro has improved in the U.S. after months of widespread shortages. During an earnings call Thursday, Eli Lilly executives said the company experienced tight supply for Mounjaro throughout most of the third quarter. But U.S. product shipments of Mounjaro have recently increased, and inventory levels at U.S. drug wholesalers have improved, according to Eli Lilly CFO Anat Ashkenazi. Eli Lilly has also invested more than $3 billion to build two new manufacturing sites in its home state of Indiana. Eli Lilly's main rival in the weight loss drug space, Novo Nordisk , is still navigating its own supply constraints of diabetes drug Ozempic and obesity treatment Wegovy.

Persons: Eli Lilly, Mounjaro, Eli Lilly's, Anat Ashkenazi, Ashkenazi, David Ricks, Ricks, we're, Wegovy, Eli Lilly's Mounjaro Organizations: Novo Nordisk, Pharmacy, Food, Pfizer Locations: Provo , Utah, U.S, North Carolina, Indiana, Novo

☆ SafeMoon executives charged in US with fraud related to crypto token
▼ + stars: | 2023-11-01 | by ( Jonathan Stempel | Companies Need To Integrate Climate Reporting Across Functions To Comply With California S New Law | Henry Engler | ) www.reuters.com time to read: +2 min

The U.S. Securities and Exchange Commission filed related civil charges against the defendants, and over the Provo, Utah-based company's alleged unregistered sale of the SafeMoon token. Lawyers for SafeMoon and the individual defendants did not immediately respond to requests for comment. According to court papers, SafeMoon also promised investors that the token's features would "drive the price to stratospheric all-time highs" and "Safely to the Moon." SafeMoon was valued at about $50 million on Wednesday afternoon, losing more than half its value after the charges were announced, according to CoinMarketCap. Reporting by Jonathan Stempel in New York; editing by Jonathan OatisOur Standards: The Thomson Reuters Trust Principles.

Persons: Al Drago, Kyle Nagy, Braden John Karony, Thomas Smith, SafeMoon, Ivan Arvelo, Smith, BRO, Karony, Nagy, Gary Gensler, Jonathan Stempel, Jonathan Oatis Organizations: U.S . Department of Justice, REUTERS, U.S . Securities, Exchange Commission, SafeMoon, McLaren, Porsche, Homeland Security Investigations, SEC, Thomson Locations: American, Washington , U.S, Brooklyn, Provo , Utah, New York, Provo, Bethlehem , New Hampshire

☆ 10 smaller US cities with booming tech scenes
▼ + stars: | 2023-10-30 | by ( Jordan Pandy | ) www.businessinsider.com time to read: +2 min

Three metros in Utah are among the mid-size cities with the most advanced tech talent. From that list, it then ranked cities by their share of tech workers with at least one of the in-demand tech skills previously identified. Cities with more to offer than just a robust tech scene scored high in where advanced tech talent is concentrating. Fayetteville, Arkansas, which ranked as the mid-size city with the second-highest concentration of advanced tech talent, has attracted tech workers seeking a more laid-back lifestyle than larger cities with a high concentration of tech talent, like Austin, Texas . Here are the top 10 mid-size cities ranked by their concentration of advanced tech workers, according to the Burning Glass Institute.

Persons: —, San, Matt Sigelman, Ann Organizations: Service, Burning Glass, Street Journal, Glass Institute, Journal . Tech Locations: Fayetteville , Arkansas, Rochester , New York, Utah, San Francisco, Seattle, Provo , Utah, Ann Arbor , Michigan, Boise City , Idaho, Salt Lake City , Utah, Austin , Texas

REUTERS/George Frey Acquire Licensing RightsBERLIN, Oct 24 (Reuters) - Several people were hospitalised in Austria after using suspected fake versions of the diabetes drug Ozempic, the country's health safety body said, the first report of harm to users in a widening European hunt for counterfeiters. Regional regulator, the European Medicines Agency (EMA), last week warned about pre-filled injection pens falsely labelled as Ozempic, which has seen surging demand for its weight-loss benefits. The maker of the drug, Novo Nordisk (NOVOb.CO), has flagged a surge in online offers of fake versions of Ozempic as well as its weight-loss drug Wegovy, both based on semaglutide. The BASG did not provide an exact number of people harmed by the fake Ozempic, or say how long-lasting the adverse effects would be on their health. That person likely did not procure the fakes from an official pharmacy, it said, warning that fake injection pens may still be in circulation.

Persons: George Frey, Ozempic, BASG, Wegovy, Miranda Murray, Ludwig Burger, Alexandra Schwarz, Angus MacSwan, Bernadette Baum Organizations: Novo Nordisk, Pharmacy, REUTERS, Rights, European Medicines Agency, EMA, Thomson Locations: Provo , Utah, U.S, Austria, Danish, Germany, Britain, British, Berlin, Frankfurt, Vienna

Search resuls for: "Provo"

25 mentions found